Optical Prism November - Page 39

Glimpses BLEPHEX, LLC EXHIBITS FIRST MEDICAL DEVICE FOR PAINLESS, IN OFFICE TREATMENT OF BLEPHARITIS AT AAO 2014 The first medical device that allows doctors to perform a painless, in office procedure to treat blepharitis, thus relieving patients from the chronic and irritating symptoms of inflammatory lid disease and dry eye, is being exhibited at AAO 2014, Chicago, announced by Dr. James Rynerson, MD, Board Certified Ophthalmologist, and president and CEO of BlephEx, LLC. patients over 65, and up to 35 per cent of all patients, have some form of blepharitis, Dr. Rynerson noted. “In the same way that gingivitis and tooth loss can be avoided by regular teeth cleaning and flossing, blepharitis and tear gland damage can be controlled by BlephEx treatments every four to six months, followed by nightly home maintenance. With routine maintenance blepharitis symptoms such as itching or scratchy eyes, foreign body sensation, tearing, crusting, redness and inflammation, mattering, dry eyes and eye rubbing can be significantly reduced,” according to Dr. Rynerson. For more information visit:www.BlephEx.com. The BlephEx™ hand piece enables eye care professionals to reduce scurf, bacterial debris and the biofilm, thereby improving the overall health of the eyelid, Dr. Rynerson said. BlephEx™ can save patients hundreds of dollars in the costs of prescription drops, home scrubs, humidity goggles and artificial tears that mask the symptoms but do not eliminate the cause. BlephEx removes the biofilm, completely clearing the lids of the inflammatory exotoxins that accumulate along the margins, explained Dr. Rynerson. BlephEx features a medical grade disposable, micro-sponge that spins along the edge of eyelids and lashes, exfoliating the eyelids. A numbing drop is placed in each eye prior to treatment for increased comfort. Following the six to eight minute, well-tolerated procedure, patients often report a near immediate resolution of the chronic eye irritation associated with blepharitis and an eventual resumption of normal tear production. Studies show that more than 70 per cent of Optical Prism | November-December 2014 35